Divi's Laboratories Ltd.

View in App
3673.85 -43.50 ▼-1.2%

19 April 2024, 04:01:00 PM
Volume: 11,159

Company Profile

View details >>
Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.divislabs.com
Market Cap 97,408.39 Cr.
Enterprise Value(EV) 93,799.39 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 52.10 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 70.43 Trailing Twelve Months Ending 2023-12
Industry PE 40.73 Trailing Twelve Months Ending 2023-12
Book Value / Share 491.02 Trailing Twelve Months Ending 2023-12
Price to Book Value 7.47 Calculated using Price: 3,669.30
Dividend Yield 0.82 Period Ending 2023-03
No. of Shares Subscribed 26.55 Cr. 265,468,580 Shares
FaceValue 2
About Divi's Laboratories Ltd.
The Company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.

Divi's Laboratories Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Divi's Laboratories Ltd. Performance

View details >>
1 Day
-1.17%
1 Week
-1.73%
1 Month
+4.82%
3 Month
-0.71%
6 Month
+0.91%
1 Year
+12.34%
2 Year
-18.72%
5 Year
+112.93%
10 Year
+454.21%

Divi's Laboratories Ltd. Fundamental Ratios

View details >>
9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 26.37 28.91 21.98 15.55 21 19.3 23.9 28.16 14.89
Return on Capital Employed (%) 33.06 35.57 28.75 21.68 28.5 25.36 32.07 35.06 19.36
Return on Assets (%) 18.21 22.49 17.21 11.12 15.78 15.11 19.07 22.77 12.37

Divi's Laboratories Ltd. Balance Sheet

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 3,495 4,293 5,357 5,925 6,957 7,310 9,295 11,728 12,767 12,677
Non Curr. Liab. 842 85 1,412 1,769 991 295 364 437 556 582
Curr. Liab. 776 520 659 653 847 1,821 1,728 2,454 1,533 1,011
Minority Int.
Equity & Liab. 5,112 4,898 7,429 8,347 8,795 9,425 11,387 14,619 14,857 14,270
Non Curr. Assets 2,340 1,871 3,418 3,812 4,145 3,851 4,596 5,009 5,113 5,388
Curr. Assets 2,772 3,027 4,011 4,535 4,650 5,574 6,791 9,610 9,744 8,882
Misc. Exp. not W/O
Total Assets 5,112 4,898 7,429 8,347 8,795 9,425 11,387 14,619 14,857 14,270

Divi's Laboratories Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 3,115 3,776 4,064 3,891 4,946 5,394 6,969 8,960 7,768 7,493
Other Income 45 97 75 113 156 190 63 116 345 328
Total Income 3,160 3,874 4,139 4,005 5,102 5,584 7,032 9,076 8,112 7,821
Total Expenditure -1,949 -2,358 -2,617 -2,629 -3,073 -3,571 -4,108 -5,079 -5,398 -5,533
PBIDT 1,211 1,516 1,522 1,376 2,029 2,013 2,924 3,997 2,714 2,288
Interest -3 -5 -3 -2 -5 -7 -2 -2 -2 -1
Depreciation -136 -118 -123 -142 -169 -186 -256 -312 -343 -370
Taxation -221 -267 -335 -354 -502 -443 -682 -723 -545 -534
Exceptional Items
PAT 852 1,126 1,060 877 1,353 1,377 1,984 2,960 1,823 1,383
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 852 1,126 1,060 877 1,353 1,377 1,984 2,960 1,823 1,383
Adjusted EPS 32 42 40 33 51 52 75 112 69 52

Divi's Laboratories Ltd. Cash Flow

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 557 826 1,038 1,150 776 954 1,216 1,947 1,912 2,460
Cash Fr. Inv. -305 -521 -406 -1,140 -478 -685 -83 75 -2,195 -2,708
Cash Fr. Finan. -249 -303 -631 2 -314 -246 -1,091 -35 -532 -797
Net Change 3 3 0 13 -17 23 41 1,987 -816 -1,045
Cash & Cash Eqvt 15 18 18 -4 -21 2 43 2,030 1,215 170

Divi's Laboratories Ltd. Shareholding Pattern

View details >>
9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 51.94 51.94 51.94 51.94 51.94 51.93 51.93 51.92 51.92
Public 48.06 48.06 48.06 48.06 48.06 48.07 48.07 48.08 48.08
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Divi's Laboratories Ltd. Announcements

View details >>
Fri, 12 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyDIVIS LABORATORIES LTD.
2CIN NO.L24110TG1990PLC011854
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY AA+
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkNSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: M Satish Choudhury
Designation: Company Secretary and Compliance Officer
EmailId: cs@divislabs.com
Name of the Chief Financial Officer: L Kishore Babu
Designation: Chief Financial Officer
EmailId: kishore@divislabs.com

Date: 12/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Thu, 11 Apr 2024
Certificate Pursuant To Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended March 31 2024
As per attachment.
Mon, 08 Apr 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Clippings - Intimation of notice given to shareholders in respect of transfer of equity shares to IEPF account

Divi's Laboratories Ltd. Technical Scans

View details >>
Fri, 19 Apr 2024
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
Making Lower Lows for 2 Days Making Lower Lows for 2 Days
High Increase in 1 Month High Increase in 1 Month
High Increase in 5 Years High Increase in 5 Years

Divi's Laboratories Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 365,310.75 1,525.00 +0.5%
Cipla Ltd. 108,622.88 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. 99,134.26 5,942.65 -0.3%
Mankind Pharma Ltd. 93,565.44 2,362.00 -1.5%
Zydus Lifesciences Ltd. 92,794.90 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. 88,715.85 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. 85,858.53 2,541.05 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.02 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-12 29.29 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 18.96 5,942.65 -0.3%
Mankind Pharma Ltd. Consolidated 2023-12 54.18 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.20 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 112.40 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 57.47 2,541.05 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.85 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-12 4.19 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.69 5,942.65 -0.3%
Mankind Pharma Ltd. Consolidated 2023-12 10.53 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.92 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.14 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.01 2,541.05 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 0.02 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,942.65 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,541.05 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,942.65 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,541.05 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 12.85 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,942.65 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,541.05 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,942.65 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,541.05 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,525.00 +0.5%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,345.35 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,942.65 -0.3%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,362.00 -1.5%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 925.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,152.25 +1.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,541.05 -0.2%

Divi's Laboratories Ltd. FAQ's

What is Divi's Lab share price?
Can I buy Divi's Lab shares now?
What is the Dividend Yield of Divi's Lab?
What is the Market Cap of Divi's Lab?
What are the key metrics to analyse Divi's Lab?
What is the 52 Week High and Low of Divi's Lab?
What is the trend of Divi's Lab share price?